Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
Vertex shares fell 15.4% after the company posted in-line Q4 results but disappointing Q1 2025 guidance. Adjusted earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback